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 Introduction 
Osteoporosis occurs with increased prevalence in individuals with inflammatory bowel disease 
(IBD), and as such, these patients are at risk for osteoporosis-related fractures.   Although 
bisphosphonates remain the most commonly used class of drugs for managing osteoporosis, the 
effectiveness of oral bisphosphonates in patients with IBD may be diminished due to distressing 
gastrointestinal side effects, which hinder compliance, and also due to poor absorption by 
diseased intestine. 
While intravenous bisphosphonate therapy remains an option for these patients, denosumab has 
emerged in recent years as an alternative bone-modifying agent.  Denosumab received FDA 
approval for treatment of postmenopausal osteoporosis in 2010 and clinical trials have 
demonstrated that this medication is both efficacious and well tolerated.  Hypocalcemia is a 
known adverse effect of this medication, although in clinical trials, denosumab has been well 
tolerated, and numerous trials, most notably the FREEDOM trial (and its two-year extension 
trial), have failed to demonstrate a significant risk of hypocalcemia while receiving denosumab 
[1].  However, there have been no formal studies assessing for the risk of hypocalcemia while 
receiving denosumab in patients who have gastrointestinal disorders such as IBD.  This report 
details a patient with a history of corticosteroid-treated Crohn’s disease, who developed severe, 
symptomatic hypocalcemia shortly after beginning denosumab therapy. 
Case Presentation 
A 64-year-old Caucasian woman presented to the emergency department with a two-week 
history stiffening of her hands and face, myalgias, weakness, and edema of the hands and 
feet.  Additionally, on the day of presentation, she developed garbled speech.  The patient had a 
past medical history significant for Crohn’s disease, for which she was status-post ileocolectomy 
with only six feet of remaining intestine; osteoporosis; gouty arthritis; breast carcinoma with left 
mastectomy in 2006; renal carcinoma with ablation in 2009; and lymphoma.  72 hours prior to 
initial onset of symptoms, the patient was started on denosumab to treat her osteoporosis.  Of 
note, the patient was taking prednisone 10 mg per day for the past year to manage her Crohn’s 
disease. 
Physical exam in the emergency department was remarkable for positive Chvostek and 
Trousseau signs, and patient was alert but unable to speak, due to mandibular tetany.  Blood 
testing revealed hypocalcemia with serum calcium of 3.9 mg/dL.  Other notable laboratory 
findings included a PTH of 5,679 pg/mL (normal 15-65 pg/mL), a 25-hydroxy vitamin D of 9 
ng/mL (normal 30-80 ng/mL), a creatinine of 1.4 mg/dL, and an alkaline phosphatase of 205 
IU/L.  She was admitted to the medical intensive care unit and placed on telemetry due to 
concerns that the patient might develop hypocalcemia-induced prolonged QT 
interval.  Throughout the patient’s three-day hospital stay, she received a total of 28 grams of IV 
calcium gluconate.  Additionally, she was started on calcitriol 0.25 mg/day and oral calcium (350 
mg) and vitamin D (200 IU) 3 tablets, three times per day.  At the time of discharge, the patient’s 
signs and symptoms of hypocalcemia had resolved, although her calcium level remained 
relatively low at 6.6 mg/dL.  Of note, baseline calcium and vitamin D levels were not obtained 
prior to starting the patient on denosumab. 
 Discussion 
 Inflammation-Induced Osteoporosis 
Osteoporosis is thought to be present in up to 70% of patients with IBD, depending on the 
population, due to a number of factors including inflammation, malabsorption (due to disease 
activity and/or extensive intestinal resection), generalized poor nutritional status, and 
glucocorticoid use[2,3].  Inflammation in IBD leads to bone density loss, as over-activation of T 
cells and the resulting cytokine release stimulates the receptor activator of nuclear factor KB 
ligand (RANKL).  RANKL, in turn, binds to RANK receptors on osteoclasts, promoting 
osteoclastic activity, and thus bone resorption.  In understanding this physiology, it could be 
reasoned that denosumab may be the ideal bone-modifying agent for these patients.  Denosumab, 
a human monoclonal antibody, acts by binding to and inhibiting RANKL.  This inhibitory action 
effectively counteracts the cytokine release by proinflammatory cells as it prevents osteoclast 
formation, decreases bone resorption and increases bone mass. 
Role of Malabsorption 
However, as mentioned above, this inflammatory-induced cytokine cascade is only one 
mechanism of several that are thought to contribute to the development of osteoporosis in these 
patients.  Another major contributing factor is from bone loss secondary to nutrient 
malabsorption.  Patients with Crohn’s disease, in whom the small intestine is involved—
specifically patients with inflammation, chronic fibrosis or who are status post removal of the 
terminal ileum—may have decreased absorption of vitamin D, and thus decreased calcium 
levels, due to impaired bile salt reabsorption [2].   Poor vitamin D and calcium absorption leads to 
the development of secondary hyperparathyroidism, which in turn increases bone loss as a result 
of increased resorption.  A multitude of studies exploring the prevalence of vitamin D deficiency 
in patients with Crohn’s disease have yielded variable results, with a range of 27-68%[4]. For 
example, a 2011 prospective study sought to assess for Vitamin D deficiency in 81 patients with 
Crohn’s disease, and found that 63% of studied patients had subnormal levels[5].  Interestingly, of 
these 63% of patients with low levels of vitamin D, 43% were actively taking a vitamin-D 
containing supplement.  Of note, most patients who were taking a supplement were taking a 
multivitamin containing a relatively low dose of vitamin D (200-400 IU) [5].  This finding 
suggests that providers may need a more aggressive approach for vitamin D (and calcium) 
supplementation in patients who are at risk for deficiency due to comorbid conditions 
(malabsorptive diseases, chronic kidney disease).  Osteoporosis secondary to vitamin D 
deficiency cannot be corrected with denosumab or other bone-modifying agents. 
Glucocorticoid-Induced Osteoporosis 
Glucocorticoids further contribute to osteoporosis in a number of ways.  They stimulate 
osteoclasts by increasing RANKL levels, while increasing osteoblast apoptosis and decreasing 
osteoblast function and life span.  Glucocorticoids also stimulate osteocyte 
apoptosis.  Furthermore, they inhibit calcium absorption from the gastrointestinal tract and 
induce renal calcium loss[6,7].  The role of denosumab in treating patients with IBD who are 
receiving glucocorticoid therapy is less clear.  While this medication can correct glucocorticoid-
induced osteoclast stimulation, osteoclast activity appears to play a smaller role in the 
pathogenesis of glucocorticoid-induced osteoporosis than it does in the pathogenesis of other 
types.   There are additional concerns that concurrent use of glucocorticoids and denosumab may 
increase a patient’s infection risk[6,7]. 
Hypocalcemic Effect of Denosumab 
While denosumab seems promising for treating osteoporosis in patients with IBD, osteoclast 
inhibition raises concerns for hypocalcemia, as the body has lost its means for harvesting 
additional calcium when blood levels drop.  Fortunately, this complication is rare; current 
estimates of hypocalcemia incidence while taking denosumab are 1.7%[8,9].  Despite this 
apparently low occurrence, the FDA label does caution about the potential for patients to develop 
hypocalcemia due to post-marketing reports of severe, symptomatic hypocalcemia with 
denosumab use.   Not surprisingly, patients with chronic kidney disease and malabsorption 
syndromes are most at risk for developing this complication[1].  Importantly, denosumab has not 
been formally studied in patients with gastrointestinal disorders.  The FREEDOM study, which 
is perhaps the most well-known clinical trial for assessing denosumab efficacy and safety, failed 
to uncover an increased risk of hypocalcemia in its study patients, but also excluded patients with 
any conditions that could affect bone metabolism (malabsorptive disorders, kidney disease) from 
participating in the study[10].   As such, the results of this study should not be generalized to this 
population of patients.  Patients with these conditions are clearly more likely to develop severe 
hypocalcemia while undergoing denosumab treatment because many have hypocalcemia at 
baseline. 
In 2012, the Medicines and Healthcare products Regulatory Agency (MHRA) released a report 
warning of the possible risk of severe symptomatic hypocalcemia.  Although the greater concern 
for hypocalcemia occurs with the 120 mg dose (Xgeva) which is used for prevention of skeletal 
related events in patients with bone metastases, symptomatic hypocalcemia has also been 
reported in patients receiving the 60 mg dose (prolia).  Based on these reported hypocalcemic 
events, the MHRA cautioned healthcare professionals to avoid use of denosumab 60 mg (for 
osteoporosis indications) in patients with any degree of hypocalcemia.  The MHRA also 
reiterated the importance of adequately supplementing calcium and vitamin D in patients 
receiving this medication, and vigilantly following blood levels of these nutrients in patients[11]. 
  
Learning Points  
 Osteoporosis is prevalent in patients with IBD, particularly Crohn’s disease, and its cause 
is multifactorial. 
 Denosumab, a RANKL inactivator, may prove helpful in minimizing osteoporosis 
induced by the large inflammatory component of IBD and its resulting stimulation of the 
RANKL-RANK interaction for osteoclast activation. However, concerns for 
hypocalcemia and a lack of clinical trials studying denosumab’ s effects in patients with 
malabsorptive disorders should limit its use in this patient population at this time. 
 Should denosumab be used for patients with malabsorptive disorders, it is imperative that 
these patients have normal calcium and vitamin D levels prior to beginning treatment, 
and calcium and vitamin D levels should be monitored frequently throughout duration of 
treatment.  Baseline levels must be obtained. 
 More research is needed to identify target calcium and vitamin D levels (and thus 
appropriate supplementation dosages) for osteoporotic patients with malabsorptive 
disorders who may benefit from denosumab therapy. 
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Introduction: Coxsackie virus infections occur throughout the year, but have an increased in the 
summer and fall (1). It is often self-limited and resolves with only symptomatic treatment, but 
the virus has been linked to rhabdomyolysis in case reports. Though the exact mechanism of 
viral rhabdomyolysis is still unknown, the end result is destruction of myocytes and the release 
of toxins into the circulation (2, 3). The results of rhabdomyolysis can be limited to myalgia or 
can be severe enough to require dialysis (2,4). It is therefore important to recognize viral causes 
